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Introduction
Hypogammaglobulinemia is the most common chronic
immune defect in patients with lymphoproliferative disorders
(LPDs). The defect can be an intrinsic characteristic of the dis-
ease, as in chronic lymphocytic leukemia (CLL) and/or be due
to the chemo-immunotherapy regimens employed for the
hematologic malignancy. In particular, anti-CD20 monoclonal
antibody (rituximab) is known to be associated with the
development of prolonged secondary hypogammaglobuline-
mia.1 Long-lasting antibody defects have been reported fol-
lowing rituximab treatment (both in monotherapy or in com-
bination with chemotherapy) in patients with indolent and
aggressive B-non-Hodgkin lymphomas (including CLL),2-4
post-transplant Epstein-Barr virus-associated LPDs,5-8 post-
autologous bone marrow transplantation,9-11 and HIV-associ-
ated lymphomas.12 It is worthy of note that the use of ritux-
imab in the setting of non-hematologic conditions (autoim-
mune cytopenias13 and rheumatoid arthritis14) has extended
the spectrum of secondary hypogammaglobulinemias follow-
ing anti-CD20 therapy. 
A recent Cochrane review suggests that the use of prophy-
lactic intravenous immunoglobulins (IVIg) may be considered
in patients with hypogammaglobulinemia  secondary to CLL
or multiple myeloma who experience recurrent infections,
since IVIg could significantly decrease the number of infec-
tions and the use of antibiotics, reducing hospitalization need
and loss of working days.15 This is consistent with the NIH
consensus paper recommendations.16 Despite these consider-
ations, until now only a few studies have evaluated the
potential prophylactic role of polyvalent immunoglobulins in
hypogammaglobulinemic patients with LPDs. 
Subcutaneous immunoglobulins (SCIg) have been shown
to be safe, cost-effective and greatly appreciated in terms of
health-related quality of life (HRQL)17-22 in patients with pri-
mary immunodeficiencies (e.g. common variable immunode-
ficiency). SCIg can be self-administered at home, do not
require venous access or systemic pre-medication, is charac-
terized by a gradual absorption of the drug and a decrease in
the incidence of systemic adverse effects (AEs).22-24 Local reac-
tions, which are specific for subcutaneous treatment, are usu-
ally mild and do not affect the good tolerability of the treat-
ment.25
In this study, we evaluated the efficacy of SCIg therapy in
61 patients with LPDs and secondary hypogammaglobuline-
mia. Specifically, we retrospectively analyzed clinical data
obtained in a cohort of patients with LPDs treated with
immunoglobulin replacement therapy, comparing the
obtained results with IVIg and SCIg in terms of efficacy, safe-
ty and HRQL parameters. Our data clearly demonstrate that
©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.101261
The online version of this article has a Supplementary Appendix.
Manuscript received on November 26, 2013. Manuscript accepted on March 18, 2014.
Correspondence: carlo.agostini@unipd.it
Intravenous immunoglobulin replacement therapy represents the standard treatment for hypogammaglobulinemia
secondary to B-cell lymphoproliferative disorders. Subcutaneous immunoglobulin infusion is an effective, safe and
well-tolerated treatment approach in primary immunodeficiencies but no extensive data are available on their use in
secondary hypogammaglobulinemia, a frequent phenomenon occurring after treatment with anti-CD20 monoclonal
antibodies in lymphoproliferative disorders. In this retrospective study we evaluated efficacy (serum IgG trough lev-
els, incidence of infections per year, need for antibiotics) and safety (number of adverse events) of intravenous (300
mg/kg/4 weeks) versus subcutaneous (75 mg/kg/week) immunoglobulin replacement therapy in 61 patients. In addi-
tion, the impact of the infusion methods on quality of life was compared. All patients were treated with subcuta-
neous immunoglobulin, and 33 out of them had been previously treated with intravenous immunoglobulin. Both
treatments appeared to be effective in replacing Ig production deficiency and in reducing the incidence of infectious
events and the need for antibiotics. Subcutaneous immunoglobulin obtained a superior benefit when compared to
intravenous immunoglobulin achieving higher IgG trough levels, lower incidence of overall infection and need for
antibiotics. The incidence of serious bacterial infections was similar with both infusion ways. As expected, a lower
number of adverse events was registered with subcutaneous immunoglobulin, compared to intravenous
immunoglobulin, with no serious adverse events. Finally, we observed an improvement in health-related quality of
life parameters after the switch to subcutaneous immunoglobulin. Our results suggest that subcutaneous
immunoglobulin is safe and effective in patients with hypogammaglobulinemia associated to lymphoproliferative
disorders.
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ABSTRACT
SCIg represent a valuable alternative for immunoglobulin
replacement in patients with secondary IgG defects,
including those following anti-CD20 therapy.
Methods
Sixty-one patients were treated with SCIg for hypogammaglob-
ulinemia secondary to B-cell lymphoproliferative disorders.
Patients’ characteristics are listed in Table 1. The mean duration of
therapy with SCIg was 19 months (range 3-56 months), at a mean
dose of 75 mg/kg/week of 16% or 20% subcutaneous preparation
(35 patients used Subcuvia®/Baxter and 26 patients used
Vivaglobin®/CSL Behring; these 26 patients were recently shifted
to Hizentra®/CSL Behring). Thirty-three of 61 patients had been
previously treated with IVIg (average duration of therapy 42
months, range 3-141 months) at a mean dose of 300
mg/kg/month. In more than 95% of patients we used IgVENA by
Kedrion. The switch between the two types of infusion was done
without a wash-in/wash-out phase: patients switching from IVIg
had their first administration of SCIg 15-22 days after their last
IVIg.18 Eighteen of the 61 patients died during follow up because
of complications related to the underlying disease. Forty-two of 61
patients had been treated with the anti-CD20 monoclonal anti-
body before the onset of hypogammaglobulinemia (range 6-25
administrations). Replacement therapy was initiated in subjects
with hypogammaglobulinemia (IgG <600 mg/dL) complaining of
serious non-neutropenic infectious events, or when an increase in
the incidence of non-neutropenic infections requiring antibiotic
therapy was detected (more than 2 episodes in 12 months).
Patients had been evaluated monthly during replacement therapy
with IVIg, every three months during replacement therapy with
SCIg. During SCIg treatment patients were required to keep a
diary in which they listed all Ig infusions, infusion-related AEs and
details regarding any infectious events. Concerning IVIg treat-
ment, infusion-related AEs were detected by the staff during the
infusion procedure while patients were required to keep a diary to
record any infectious event. At each outpatient visit, we recorded
IgG levels, any episodes of fever, signs or symptoms of infection,
needs for antibiotics and hospitalization for infectious events.
Among all infectious events detected, serious bacterial infections
(SBI) were defined as pneumonia, meningitis, sepsis, endocarditis
diagnosed by a practising physician according to standard medical
procedures (physical examination, laboratory tests, bacterial cul-
tures, imaging).  Similarly, we considered any reported adverse
event (AEs) that occurred during and/or following the weekly
infusion of SCIg or the monthly infusion of IVIg. We also consid-
ered the number of patients requiring local or systemic pre-med-
ication prior to replacement therapy. Clinical data recorded during
the follow up were analyzed at 3 different time frames: in the 12
months before replacement therapy, during IVIg and during SCIg.
To evaluate the efficacy of replacement therapy, we considered
the IgG trough level (for SCIg at the steady state, after at least 12
weeks of therapy26), the annualized rate of overall infection and
SBI per patient, the number of cycles of antibiotics needed. To
compare safety, we considered the number of patients complain-
ing of AEs. HRQL was assessed using a SF-36-inspired question-
naire, administered to the 33 patients shifted from IVIg to SCIg.
Informed consent was obtained from all patients and the study
was approved by the local ethics committee.
Results
Serum IgG trough levels was higher following replace-
ment therapy with SCIg than with IVIg. Mean IgG level
ranged from 380±119 mg/dL at baseline to 474±116
mg/dL following IVIg (25% increase) and to  660±173
mg/dL following SCIg (73% increase); the difference of
the serum trough levels of IgG obtained with SCIg result-
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Table 1. Patients’ demographics and characteristics.
Characteristic                                                              Total n=61 (%)
Sex, n. (%)                                                   Male                             35 (57)
                                                                      Female                           26 (43)
Age class, n. (%)                                      20 to 64                           20 (33)
                                                                         >65                              41 (67)
Mean age, years                                                                                   67,7
Diagnosis, n. (%)                                      B-CLL                            40 (66)
                                                                         NHL                              21 (34)
Rituximab                                                                                           42 (69)
n.: number of patients.
Figure 1. Mean serum IgG trough levels
(mg/dL).  Serum IgG trough levels gave
higher results following replacement thera-
py with SCIg than with IVIg.  *P< 0.05. IVIg:
intravenous immunoglobulin; SCIg: subcu-
taneous immunoglobulin; pre-treatment:
before replacement therapy.
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ed statistically significant compared with the trough levels
obtained with IVIg (P<0.05) (Figure 1).  In the 12 months
before replacement therapy, we reported 24 cases of SBI
(12 cases of bacterial pneumonias, 8 sepsis, 3 cases of bac-
terial meningitis, 1 endocarditis), resulting in an annual
rate of 0.46 episodes per patient-year; there were 130
episodes of infections (2.79 per patient-year). We reported
2.35 cycles of antibiotics per patient-year.  During IVIg
treatment, among 33 patients we reported 12 cases of SBI
(10 cases of bacterial pneumonias, 2 sepsis), resulting in an
annual rate of 0.10 episodes per patient-year. There were
260 episodes of infections (2.29 per patient-year); we
reported 1.82 cycles of antibiotics per patient-year. During
SCIg treatment, among 61 patients we detected 11 cases
of SBI (8 cases of bacterial pneumonias, 2 sepsis, 1 case of
bacterial meningitis), resulting in an annual rate of 0.11
episodes per patient-year. There were 170 episodes of
infections (1.76 per patient-year); we reported 1.43 cycles
of antibiotics per patient-year.
In all 3 groups, the most frequently reported infections
involved respiratory tract (upper respiratory infections,
nasopharyngitis, pneumonias) (Table 2). When bacterial
cultures where available, most of them were positive for
S. Pneumoniae and H. Influenzae, pathogens known to be
related to hypogammaglobulinemia and responsible for
infections in PID (data not shown).
In the 33 subjects treated with IVIg, we observed 11
cases of fever after infusion (34% of patients), 5 cases of
diffuse skin reactions (15%), 3 cases of sickness / dizziness
/ headache / nausea (9%), 3 cases of dyspnea (9%), 1 case
of anaphylaxis (3%). Eighteen of 33 subjects (55%) never
complained of any adverse infusion-related reactions, 17
subjects (52%) required administration of a pre-medica-
tion with steroids and antihistamines prior to infusion of
IVIg in order to ensure therapy was safer and better toler-
ated. In 61 subjects treated with SCIg, tolerability was
good, and the majority of AEs were of mild or moderate
intensity. Infusion-site reactions were observed in 6
patients (10%), while 4 cases of fever were reported fol-
lowing the infusion (7%) and 2 subjects reported
headache after the infusion (3%). As expected, the inci-
dence and the intensity of infusion-site reactions
decreased over time. It is worthy of note that we did not
observe any case of infection at the site of subcutaneous
infusion. Only 2 patients after a few weeks of SCIg
returned to IVIg administration because of a local poor tol-
erance to subcutaneous administration. In one case, this
was because of infusion-site reactions of moderate inten-
sity that lasted for 5-7 days; the patient preferred to with-
draw SCIg and re-start IVIg replacement therapy. Another
patient preferred to shift back to IVIg, complaining of
moderate local reactions associated with fever. Fifty of 61
patients (82%) never complained of any adverse reaction
to infusion of SCIg, and only one patient (2%) required
pre-medication with non-steroid anti-inflammatory drugs
(NSAIDs) prior to treatment (Table 3). 
Considering only the 33 patients who shifted from IVIg
to SCIg, serum IgG trough levels achieved with SCIg were
statistically higher than the level obtained with IVIg (652
mg/dL with SCIg vs. 465 mg/dL with IVIg) (P<0.01). In
these patients, we performed the same analysis of efficacy
and safety described above, and found data quantitatively
and qualitatively similar to those found by considering the
entire cohort. 
Analysis of adapted quality of life questionnaires
showed that most of the patients considered the shift
from IVIg to SCIg as an improvement in their quality of
life (details are shown in the Online Supplementary
Appendix). Concerning the impact on infectious events
during normal daily activities, patients perceived only a
slight improvement, linking this effect to the lower inci-
dence of infections. The better safety profile after SCIg
was considered by patients as an important gain in their
health status, likely since they perceived that SCIg do not
cause major AEs with respect to IVIg. The possibility of
home infusion of SCIg was considered a big improvement
in the quality of life. Taken together, all these aspects
(adverse events, infectious events, home-therapy) in the
last question of the questionnaire, the majority of patients
rated SCIg as an important improvement in their quality
of life.  
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Table 2. Infections reported before and during replacement therapy. In
all 3 groups, the most frequently reported infections involved respira-
tory tract (upper respiratory infections, nasopharyngitis, pneumonias).
Type of infection                               Pre Ig        IVIg (n=33)        SCIg 
                                                        (n=61)          n. events        (n=61)
Pneumonias                                                 12                       10                      8
Meningitis                                                      3                         0                       1
Endocarditis                                                  1                         0                       0
Sepsis                                                             8                         2                       2
Upper respiratory tract infection           51                      123                    71
Pyrexia                                                           19                       51                     29
Genital and urinary tract infection          6                         8                       4
Herpes zoster                                               3                         8                       3
Cutaneous infections                                  3                        10                      7
Flu-like syndrome                                        8                        22                     20
Nasopharyngitis                                            3                        12                     11
Ear infection                                                 3                         5                       3
Periodontal abscess                                    1                         1                       2
CMV infection                                               1                         1                       1
Herpes virus infection                                1                         5                       2
Gastroenteritis                                             7                        10                      6
IVIg: intravenous immunoglobulin; SCIg: subcutaneous immunoglobulin; Pre Ig: before
replacement therapy; n: number of patients.
Table 3. Treatment-related adverse events. SCIg has a better safety
profile compared to IVIg, with no systemic or clinically relevant AEs;
short lasting infusion-site reaction was the most frequent adverse
effect.
                                                                 IVIg                           SCIg 
                                                                (n=33)                        (n=61)
Adverse event    Number of patients affected (%)
Infusion-site reactions                                         0                                   6 (10)
Fever                                                                   11 (33)                               4 (7)
Diffuse skin reactions                                     5 (15)                                   0
Dyspnea                                                                3 (9)                                    0
Anaphylaxis                                                          1 (3)                                    0
Sickness/dizziness/headache/nausea            3 (9)                                 2 (2)
Premedications, n. (%)                                  17 (52)                               1 (2)
n.: number of patients.
Discussion
A recent systematic review compared replacement
therapy with IVIg and SCIg in primary and secondary
immunodeficiencies.27 In all the included studies, the
number of participants was low, in most of them less than
20. Only 3 studies reported the rate of SBI with SCIg, but
none of them included a comparison with IVIg. No study
reported data sufficient to compare the need for antibi-
otics. Regarding secondary immunodeficiencies, only one
study was available that retrospectively compared IVIg
and SCIg in children after hematopoietic stem cell trans-
plantation.28 In this study, 12 children were treated with
SCIg. The conclusion of the review was that, despite the
fact that it is still possible to admit that SCIg are safe and
effective in primary and secondary hypogammaglobu-
linemia, good quality studies are lacking.
This study clearly shows that, in our cohort of patients
with LPDs and hypogammaglobulinemia treated or not
with “Ig depleting” chemotherapy regimens, SCIg are
effective in maintaining adequate levels of serum IgG,
with an efficacy which is superior to that shown follow-
ing IVIg. Our results were obtained using a starting
dosage of SCIg superimposable on the previous IVIg
dose. Dosages were further individualized in each patient
according to serum IgG trough levels, with the aim of
maintaining IgG trough level above 400 mg/dL. This has
been shown to be effective in preventing the develop-
ment of serious infections in a prospective study in PID.29
As in primary antibody deficiencies, the dosages of sub-
stitutive therapy were also upward adjusted as needed to
minimize infection, identifying the ‘biological’ IgG trough
level effective in each patient.30 The mean Ig monthly
dose needed was almost identical for IVIg and SCIg even
after individualization. The higher trough level of serum
IgG achieved with SCIg can be explained by pharmacoki-
netic studies on immunoglobulin replacement therapy in
primary hypogammaglobulinemia: the lower level of IgG
achieved with IVIg despite a superimposable dosage is
due to the rapid decrease in IgG level between two sub-
sequent infusions from peak post-infusion to trough level.
SCIg administration, at the steady state, avoids this
decrease, maintaining a more physiological and stable
level of IgG between infusions.26 In our cohort, replace-
ment therapy with SCIg was associated with a reduced
rate of overall infection per patient-year and a reduction
of the need for antibiotics compared to IVIg; the rate of
SBI per patient-year was similar with IVIg and SCIg.
Thus, despite the fact that the number of patients does
not allow definitive conclusions to be drawn, a better pro-
tection against infections seems to be reached with SCIg,
likely due to the higher IgG trough levels and lower IgG
variability that are obtained using the subcutaneous
route. 
SCIg infusions were self-administered by the patient or
with the help of a relative at home after at least 3 educa-
tional infusions with trained nurses and under medical
supervision in our Outpatient Clinic. SCIg therapy has
been well tolerated, with no systemic or clinically rele-
vant AEs; the expected mild, short-lasting infusion-site
reaction was the most frequent adverse effect, with an
incidence that decreased over time. Interestingly, the fre-
quency of cutaneous reactions was significantly lower in
patients with secondary immunodeficiency in compari-
son to our cohort of PID patients (data not shown), maybe
as a consequence of the broad effect of chemotherapy on
the immune system. According to this hypothesis, the
resulting ‘anergic-like’ condition does not allow an effec-
tive cutaneous migration of immune cells, limiting the
basis of a local adverse reaction. Despite this considera-
tion, none of the patients complained of injection site
infections, although a higher infectious risk is typical of
their condition. Considering systemic adverse events, as
expected, SCIg therapy resulted in a lower frequency of
episodes (Table 3), resembling the situation already
described in PID.19-25 Interestingly, one of our patients
experienced a severe anaphylactic reaction following IVIg
but tolerated substitutive therapy with SCIg. Again, this
observation is consistent with the favorable safety profile
of SCIg therapy already reported for PID.
Other potential benefits of SCIg should be considered
in patients with hematologic malignancies. Venous access
often represents a great concern after chemotherapy
treatments. SCIg provide the possibility of avoiding the
use of central and peripheral venous accesses, favoring
their preservation and reducing the risk of access–related
infections (and subsequent bloodstream infections). The
flexibility of SCIg treatment and the possibility of a self,
home-based infusion represent a further advance for
patients who usually need an elevated number of outpa-
tient visits during the period of therapy. This improve-
ment in the quality of life is confirmed by the analysis of
the questionnaire administered to the cohort of patients.
In our case series, HRQL was assessed using a SF-36-
inspired questionnaire. SF-36 itself, already used and val-
idated for SCIg-treated PID patients,25 was not suitable in
this study since most of the general aspects investigated
by the questionnaire could have been influenced by the
underlying LPD. Thus we decided to highlight only the
aspects related to infectious events, hospitalization and
loss of working days, Ig infusion and related AEs. The
questionnaire is available in the Online Supplementary
Appendix. 
Hypogammaglobulinemia is an intrinsic aspect of LPD,
and the main aim of our study was to evaluate the effec-
tiveness of the use of SCIg in patients with LPDs,
hypogammaglobulinemia and recurrent infections, inde-
pendently from the kind of therapy employed. Regarding
rituximab treatment, we should emphasize that most of
our patients were treated with this drug (alone or in asso-
ciation with other cytotoxic drugs) before the onset of
hypogammaglobulinemia, but to describe the role of rit-
uximab treatment in the onset or worsening of the
immunological defect is beyond the purpose of this study.
In any case, it is well known that anti-CD20 treatment is
associated with a high frequency of hypogammaglobu-
linemia and symptomatic hypogammaglobulinemia, and
that replacement therapy with IVIg can reduce the inci-
dence of infections in hypogammaglobulinemic patients.1
In the present study, we excluded from the case series 6
patients with autoimmune disorders treated with
immunosuppressive drugs and rituximab, and 2 patients
with acute myeloid leukemia who had undergone
hematopoietic stem cell transplantation, who developed
hypogammaglobulinemia needing Ig replacement thera-
py. It is important to report that even in these few
patients the use of SCIg was effective, safe and well tol-
erated. The use of the anti-CD20 monoclonal antibody
rituximab is expanding in several autoimmune disorders,
including rheumatoid arthritis,31-33 immune thrombocy-
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topenic purpura,34,35 systemic lupus erythematosus,36
Sjogren syndrome, anti-neutrophil cytoplasmic antibody-
associated vasculitis, mixed cryoglobulinemia, solid organ
transplantation, renal disease, and neurological diseases.37
Thus, in our Clinical Immunology Unit, a further study is
in progress on the putative role of SCIg in the prevention
of hypogammaglobulinemia-related infections in non-
neoplastic conditions after rituximab therapy. In fact, it
might be anticipated that in the forthcoming years the use
of SCIg to correct the secondary B-cell defect might
become important also in other immune-mediated disor-
ders effectively treated with anti-CD20 mAb. 
A final comment concerns the pharmaco-economic
impact of the use of SCIg in LPDs. It is interesting to note
that it has been clearly demonstrated that SCIg replace-
ment therapy involves lower costs than IVIg in subjects
with PID, mainly due to the reduced need for Outpatient
Clinic access.38 In this regard, we would like to underline
that, in our department, the shift from IVIg to SCIg signif-
icantly reduced the need of outpatients’ visits related to
hypogammaglobulinemia. During IVIg therapy, patients
were forced to have monthly access for replacement ther-
apy; but once SCIg treatment is well established, follow up
for hypogammaglobulinemia basically required no more
than one visit and one serum IgG test every three months.
Pharmaco-economic data have not been collected in this
study but we are planning to evaluate whether a home-
based SCIg therapy reduces costs both for the Healthy
Service and for the family. In fact, it is likely that a signifi-
cant reduction in terms of days of hospitalization and
working days lost may account for a more favorable phar-
maco-economic profile of subcutaneous immunoglobulin
replacement therapy also in subjects with LPDs. 
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